NASDAQ$BCAB
Bioatla Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Bioatla Inc reported a net loss of $6.3 million for the first quarter of 2026 amid ongoing strategic review and cost reductions.
Bioatla Inc continued its Phase 1 trial for BA3182 while pausing further enrollment and implementing a 70% workforce reduction as part of a formal strategic options process. The company recorded a net loss of $6.3 million, down from $15.3 million in the prior-year quarter, driven by lower R&D and G&A expenses. Cash and cash equivalents declined to $2.0 million, raising substantial doubt about the company's ability to continue as a going concern without additional funding or a successful strategic transaction.
- Net loss narrowed to $6.3 million from $15.3 million year-over-year due to reduced operating expenses following the March 2026 restructuring.
- R&D expenses fell 63% to $4.6 million as Phase 2 trials completed and workforce was reduced by approximately 70%.
- Company initiated formal strategic review process including potential asset sales, licensing, or partnerships while preserving capital.
- Cash position of $2.0 million as of March 31, 2026 is insufficient to fund operations for twelve months, prompting going concern disclosure.
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
Company is actively exploring strategic options including asset sales and partnerships while implementing cost containment measures and re-evaluating clinical development timelines.
Tailwinds
- Received $4.5 million upfront payment commitment from Context Therapeutics amendment in May 2026
- Net loss significantly reduced year-over-year through restructuring
- Ongoing patient treatment and follow-up in Phase 1 BA3182 study
Headwinds
- Substantial doubt about ability to continue as going concern
- Paused further enrollment in Phase 1 BA3182 study pending strategic outcome
- Cash runway insufficient without additional financing or transaction
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2026
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+8.7%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.8% | — | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro